New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
10:17 EDTJNJEarnings Preview: J&J investors will focus on catalysts, operating leverage
Johnson & Johnson (JNJ), a diversified, global healthcare conglomerate, is scheduled to report fourth quarter earnings before the open on Tuesday, January 21, with a conference call scheduled for 8:30 am ET. EXPECTATIONS: Analysts are looking for EPS of $1.20 on revenue of $17.95B, according to First Call. The consensus range for EPS is $1.19-$1.22 on revenue of $17.82B-$18.09B. LAST QUARTER: Johnson & Johnson reported Q3 adjusted EPS of $1.36 against estimates for $1.32 on revenue of $17.6B against estimates for $17.46B. At the time of its Q3 earnings release, J&J also raised its FY13 EPS view to $5.44-$5.49 from $5.40-$5.47. STREET RESEARCH: In a note to investors on January 7, RBC Capital said it expects the company's pharmaceutical franchise to continue to deliver above industry average revenue growth, and it predicts that the company will continue to have operating leverage, enabling its EPS to surpass consensus levels over the next several years. The firm raised its price target on J&J to $104 from $88. On January 10, Barclays downgraded shares of J&J to Equal Weight from Overweight. Barclays downgraded Johnson & Johnson citing limited catalysts and valuation.The firm kept its price target remains $99. PRICE ACTION: Since its last earnings report, shares of J&J are up approximately 5%. Over the last year, shares are up over 30%.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2015
07:27 EDTJNJJohnson & Johnson drug business likely to remain resilient, says Wells Fargo
Subscribe for More Information
July 29, 2015
12:17 EDTJNJMedivation plummets after Cowen highlights slowing Xtandi trends
Subscribe for More Information
11:23 EDTJNJMedivir says Janssen's Alios BIopharma starts Phase I AL-704 trial
Subscribe for More Information
July 28, 2015
07:05 EDTJNJMacroGenics reports MGD011 advances into clinical development
Subscribe for More Information
July 27, 2015
10:40 EDTJNJLeerink major pharma analyst holds an analyst/industry conference call
Subscribe for More Information
July 23, 2015
17:51 EDTJNJJanssen submits sNDA to update label for Olysio
Subscribe for More Information
July 22, 2015
10:15 EDTJNJThoratec downgraded to Market Perform from Outperform at Northland
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use